CClinicalTrials.gg
Sign In
SuspendedNCT06240455Updated May 8, 2025

Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

A Phase 2 interventional study of WP1302 and WP1302 placebo in Graves Disease, sponsored by Worg Biotherapeutics Inc.. Suspended at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Worg Biotherapeutics Inc. · Phase 2, Interventional, and Treatment

Why this study was suspended
Not feasible to recruit suitable subjects
Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 2, double-blind, placebo controlled, Methimazole (MMI) withdrawal study in subjects with Graves' disease. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with Methimazole period of 12 weeks; a Full dose of WP1302 or placebo with Methimazole tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.

After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter [grade 0 or 1; grade 2], WHO classification) of 1:1:1:1 to either any group of Methimazole with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of Methimazole with placebo.

All the subjects will subsequently be enrolled in an extended safety follow-up period for an additional 6 months. Subjects who remain euthyroid will continue to be monitored for efficacy during the long-term follow-up.

Read the detailed description

This is a Phase 2, double-blind, placebo controlled, Methimazole (MMI) withdrawal study in subjects with Graves' disease. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with Methimazole period of 12 weeks; a full dose of WP1302 or placebo with Methimazole tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.

After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter [grade 0 or 1; grade 2], WHO classification) of 1:1:1:1 to either any group of Methimazole with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of Methimazole with placebo.

Subjects who have a confirmed diagnosis of Graves' disease based on medical history and/or physical examination and laboratory evidence, well controlled, with normalized thyroid function tests, and have received stable background Methimazole (i.e., not requiring dose adjustments) not exceeding 20 mg daily for at least 8 weeks and no more than 24 weeks are eligible to this study. All subjects enrolled in this study will receive Methimazole treatment in titration period.

During the titration period, subjects will receive WP1302 or placebo by subcutaneous (S.C.) injection every 2 weeks (Q2W) for 12 weeks while continuing MMI (see "Dosing" below). The dose of WP1302 will be titrated up to the target dose assigned to the subject during this period (see "Dosing" below). Thyroid symptoms and function tests will be evaluated every 2 weeks. The investigator may adjust the frequency of thyroid function tests based on safety considerations. If a subject does not maintain euthyroidism, which is defined as total T3 60-180 ng/dL, free T4 0.8-1.8 ng/dL, and TSH 0.5-5 mU/L, during the "WP1302 titration period", the subject will be discontinued from Investigational Medicinal Product (IMP) (i.e., WP1302 or placebo) and the subject is still required to complete the end-of study visit.

During the 26-week full dose of WP1302 with Methimazole tapering period, subjects who have maintained euthyroidism during the "WP1302 titration period" will be dosed with WP1302 at 400, 800, or 1200 μg with down-titrated Methimazole. Thyroid symptoms and function tests will be evaluated every 2 weeks. The investigator may adjust the frequency of thyroid function tests based on safety considerations. Subjects who experience disease relapse will be treated with Methimazole as first-line therapy (see "Management of Relapse and Rescue Medication" below).

At the end of the full dose of WP1302 with Methimazole tapering period, subjects will have 4 weeks of follow-up, and complete an end-of-study visit at Week 42. All the subjects will subsequently be enrolled in an extended safety follow-up period for an additional 6 months. Subjects who remain euthyroid will continue to be monitored for efficacy during the long-term follow-up.

02

Conditions studied

  • Graves Disease

Keywords

  • Graves' disease
  • preventing disease relapse
  • relapse rate
  • thyroid function
03

In context

Graves Disease

150 studies on the registry are indexed under Graves Disease; 53 are open to participants now.

This study's planned enrollment of 176 is above the median of 60 across 92 interventional studies indexed under Graves Disease.

Browse Graves Disease studies →

Lead sponsor

This is the only study on the registry with Worg Biotherapeutics Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18 to 65 years at the time of informed consent.
  2. Confirmed diagnosis of Graves' disease through medical history and/or physical examination, laboratory evidence as documented by a serum TSH\<0.5 mU/L and either a serum total T3 >180 ng/dL or a serum free T4 > 1.8 ng/dL.
  3. Current use of MMI at stable dose not exceeding 20 mg daily for at least 8 weeks and no more than 24 weeks by the baseline (Week 0).
  4. 60 ng/dL \< serum total T3 ≤ 180 ng/dL, 0.8 ng/dL \< serum free T4 ≤1.8 ng/dL, and 0.5 mU/L ≤ serum TSH \<5 mU/L at the Screening Visit.
  5. Willing and able to give written informed consent, agree to provide contact with the endocrinologist (or other appropriate trained healthcare provider), and to comply with protocol assessments/procedures.
  6. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study, and until at least 6 months after the last dose of WP1302.

Female subjects of child-bearing potential must use a highly effective method of contraception throughout the entire duration of the study and for at least 6 months after the last dose of WP1302.

Exclusion criteria

Exclusion Criteria:

  1. Currently using biotin supplements.
  2. Known history of allergy to the ingredients of WP1302, or hypersensitivity reaction that in the opinion of the investigator would exclude the subject's participation in the study.
  3. Previous treatment with radioiodine or (partial or complete) thyroidectomy.
  4. Subjects with known pituitary disease, such as traumatic brain disease, hyperprolactinemia, and hypophysitis.
  5. Treatment with steroids (administered via the oral and/or parenteral routes) within 3 months prior to baseline or requiring intermittent use of systemic steroids for disease management (such as severe asthma), inhaled steroids are not prohibited.
  6. History of hyperthyroidism not caused by Graves' disease (e.g., toxic multinodular goiter, autonomous thyroid nodule, or acute inflammatory thyroiditis).
  7. Subjects who may have thyroid nodules that require alternative intervention.
  8. Symptoms and signs of thyroid storm such as fever, profuse sweating, vomiting, diarrhea, delirium, severe weakness, seizures, markedly irregular heartbeat, yellow skin and eyes (jaundice), severe low blood pressure, and coma, pyrexia with no other cause than hyperthyroidism.
  9. Subjects who have a history of intolerance or contraindication to the use of beta-blockers.
  10. Subjects with history of arrhythmia, or cardiovascular accident, or other cardiovascular disease who maybe at increased risk of cardiac adverse events from treatment or recurrence of hyperthyroidism.
  11. Subjects with history of cerebrovascular accident/transient ischemic attack, or other cerebrovascular disease who maybe at increased risk of neurologic adverse events from treatment or recurrence of hyperthyroidism.
  12. Prior treatment with immunotherapies (including rituximab), any cytokine or anti-cytokine therapy.
  13. Prior treatment with immunomodulatory drugs, such as cyclosporine A, methotrexate, and/or cyclophosphamide.
  14. Prior use of disease-related T cell-inducing therapy or peptide-tolerizing agent to treat Graves' disease.
  15. Inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase > 3 times the upper limits of the normal (ULN) at screening.
  16. Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2, calculated as individual eGFR derived from Modification of Diet in Renal Disease formula.
  17. Receiving hemodialysis or peritoneal dialysis or microdialysis or continuous venovenous hemofiltration or continuous venovenous hemodialysis.
  18. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  19. Known history of active or chronic infectious disease or any disease which compromises immune function (e.g., HIV+, HTLV-1, active Lyme disease, latent or active TB, viral hepatitis).
  20. Major surgery within 6 months prior to the screening visit or requiring ongoing active treatment after surgery irrespective of the time since surgery.
  21. Active thyroid eye disease (clinical activity score [CAS] ≥3) with functional visual impairment sufficient to cause poor quality of life, or dysthyroid optic neuropathy likely to require immunosuppressive treatment during the 30 weeks of the study.
  22. Any vaccination within 30 days prior to screening, except for influenza and coronavirus vaccines.
  23. Being pregnant, breastfeeding, or planning to become pregnant during the study.
  24. Documented presence of immunodeficiency or an immunocompromised condition including hematologic malignancy, bone marrow transplant, or known human immunodeficiency virus infection with a CD4 count \<200/mm3.
  25. Currently actively moderate-heavy using tobacco (≥10 cigarettes a day).
  26. Participating in any clinical study of any investigational medication (i.e., unauthorized medication) within 90 days prior to randomization.
  27. Any other significant medical illness or psychiatric conditions that in the opinion of the investigator, would preclude participation in the study or impair the ability to give informed consent; any other clinically apparent autoimmune disease currently requiring disease-modifying or anti-inflammatory treatment; or significant illness which has not resolved within 4 weeks prior to the planned date of first dose of WP1302.
  28. Any other conditions or prior therapies, which, in the opinion of the investigator, would make the subject unsuitable for this study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (estimated)

Study arms

  • Active comparator
    WP1302 400μg

    After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.

    Drug: WP1302 · Combination Product: methimazole

  • Active comparator
    WP1302 800μg

    After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.

    Drug: WP1302 · Combination Product: methimazole

  • Active comparator
    WP1302 1200μg

    After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.

    Drug: WP1302 · Combination Product: methimazole

  • Placebo comparator
    WP1302 Placebo

    After screening, eligible subjects will be randomized to treatment at a ratio (stratified by size of goiter \[grade 0 or 1; grade 2\], WHO classification) of 1:1:1:1 to either any group of MMI with WP1302 at a dose of 400 μg, 800 μg, or 1200 μg, or the group of MMI with placebo. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with MMI period of 12 weeks; a Full dose of WP1302 or placebo with MMI tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.

    Drug: WP1302 placebo · Combination Product: methimazole

Interventions

  • DrugWP1302

    Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

  • DrugWP1302 placebo

    Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

  • Combination productmethimazole

    Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).

06

What researchers measure

Primary outcomes

  1. Relapse rate

    To assess the relapse rate between the WP1302 and placebo treatment groups in subjects who enter the tapering phase

    Time frame: Up to 42 weeks

Secondary outcomes

  1. Replase time

    To assess the time duration from start of methimazole (MMI) tapering to disease relapse between the subjects treated with WP1302 and placebo.

    Time frame: Up to 42 weeks

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    To assess the safety and tolerability of WP1302 administered with or without methimazole (MMI) in subjects with Graves' disease

    Time frame: Up to 68 weeks including LTFU

  3. Total T3, free T4, and TSH levels

    To assess the effect of WP1302 on thyroid function (measured by total T3, free T4, and TSH levels)

    Time frame: Up to 68 weeks including LTFU

  4. Pharmacokinetics (PK) parameters (AUC, Cmax)

    To assess the pharmacokinetics (PK) parameters (AUC, Cmax) of WP1302 in plasma

    Time frame: Week 0 and Week 10

  5. Incidence of anti-drug antibodies (ADAs)

    To assess the incidence of anti-drug antibodies (ADAs) against WP1302

    Time frame: Up to 68 weeks including LTFU

Other outcomes

  1. Cytokine levels of IFN-γ, IL-2, IL-6, and IL-10

    To assess the effects of WP1302 on immune response by measuring the plasma cytokine levels of IFN-γ, IL-2, IL-6, and IL-10

    Time frame: Up to 42 weeks

  2. TSH receptor antibody (TRAb) levels

    To assess the effects of WP1302 on TSH receptor antibody (TRAb)

    Time frame: Up to 68 weeks including LTFU

  3. HLA haplotypes

    To assess potential correlations between response to WP1302 and HLA haplotypes

    Time frame: Baseline

  4. Thyroid eye disease (TED) condition

    To assess occurrence, severity, and changes in severity of thyroid eye disease (TED) in a subset of subjects

    Time frame: Up to 42 weeks

07

Study locations

7 sites
  • East Valley Diabetes and Endocrinology-Clinical Research, PLLC
    Hunt, Arizona 85143, United States
  • Alliance Research Institute
    Canoga Park, California 22110, United States
  • Paradigm Clinical Research Centers - Littleton
    Littleton, Colorado 80120, United States
  • BayCare Health System, Inc.
    Clearwater, Florida 33759, United States
  • Albuquerque Clinical Trials Inc
    Albuquerque, New Mexico 87102, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Clinical Research Solution LLC dba Endocrine and Psychiatry Center
    Houston, Texas 77095, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06240455
Lead sponsor
Worg Biotherapeutics Inc.
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Mar 31, 2026 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
May 8, 2025

Study contacts

Dylan Lee, MD
study chair · Worg Biotherapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Graves Disease→

Start the discussion